2005
DOI: 10.1056/nejmoa041109
|View full text |Cite
|
Sign up to set email alerts
|

Sargramostim for Active Crohn's Disease

Abstract: This study was negative for the primary end point, but findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

3
183
0
3

Year Published

2006
2006
2019
2019

Publication Types

Select...
6
4

Relationship

1
9

Authors

Journals

citations
Cited by 316 publications
(189 citation statements)
references
References 29 publications
3
183
0
3
Order By: Relevance
“…An alternative strategy is to block binding to lectins with bacterial components ( 68 ). Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to be eff ective in a small controlled pilot study of Crohn ' s disease patients ( 69 ), but did not show benefi t in the primary end point of response defi ned by CDAI (Crohn ' s disease activity index) decrease ≥ 70 points in a larger multinational study ( 70 ). However, signifi cant secondary outcomes of more stringent response (CDAI decrease ≥ 100) and remission relative to placebo ( P < 0.01) in this phase 2 study , evidence of steroid sparing over 22 weeks ( 71 ), and detection of anti-GM-CSF antibodies in pediatric and adult patients with Crohn ' s disease, particularly those with ileal involvement ( 72 ) and increased permeability ( 73 ), lend credibility to this approach in selected patients.…”
Section: Microbial Complications Of Ibdmentioning
confidence: 99%
“…An alternative strategy is to block binding to lectins with bacterial components ( 68 ). Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to be eff ective in a small controlled pilot study of Crohn ' s disease patients ( 69 ), but did not show benefi t in the primary end point of response defi ned by CDAI (Crohn ' s disease activity index) decrease ≥ 70 points in a larger multinational study ( 70 ). However, signifi cant secondary outcomes of more stringent response (CDAI decrease ≥ 100) and remission relative to placebo ( P < 0.01) in this phase 2 study , evidence of steroid sparing over 22 weeks ( 71 ), and detection of anti-GM-CSF antibodies in pediatric and adult patients with Crohn ' s disease, particularly those with ileal involvement ( 72 ) and increased permeability ( 73 ), lend credibility to this approach in selected patients.…”
Section: Microbial Complications Of Ibdmentioning
confidence: 99%
“…Neutrophil recruitment and activation are key steps in the intestinal innate immune response observed in IBD (6)(7)(8), and studies with animal models of colitis highlight the relationship between neutrophil infiltration and disease severity (9)(10)(11). We recently reported results of a comprehensive analysis of histopathology, changes in gene expression, and nucleic acid damage occurring during progression of lower bowel disease in Rag2 −/− mice infected with Helicobacter hepaticus (Hh) (10).…”
mentioning
confidence: 99%
“…In contrast, in experimental contact hypersensitivity, characterized by an increased GM-CSF expression (17), blockade of this cytokine had no effect on disease manifestation (18). Interestingly, in Crohn's disease, application of GM-CSF improved disease activity (19,20). Hence, GM-CSF has opposing effects in different inflammatory conditions.…”
mentioning
confidence: 99%